Further, SCLC is characterized by near universal disruption of the p53 pathway [6], and upregulation of drug efflux proteins [7,8] that limit the pro-apoptotic and anti-cancer activities of many anti-cancer drugs. The gene discussed is TP53; the disease is small cell lung carcinoma.